DEXTROSE INJECTION

The contract award SPE2DP26F7813, issued by the Defense Logistics Agency under the parent IDIQ contract SPE2DX25D9900, is a firm-fixed-price delivery order for 2 packages of DEXTROSE INJECTION (NSN 6505015015408) totaling $116.52, with delivery required by July 20, 2026, to Fort Bragg, North Carolina at FOB Destination terms, with the contractor responsible for all freight costs. The awardee, DMS PHARMACEUTICAL GROUP INC (CAGE 1UNB0), is certified as a Small Disadvantaged Business and Women-Owned Small Business under a small business set-aside, and is required to comply with FAR 52.222-50 on combating trafficking in persons, as well as other standard commercial item clauses from FAR Part 12. Packaging and marking must include the Transportation Control Number W50YF262010102, the manufacturer’s CAGE code 86491, part number 00409751716, and all applicable identifiers from Blocks 1 and 2 of the order form, with shipments required to be sent via the fastest traceable means and explicitly prohibited from using Parcel Post. The Government performs acceptance at the delivery point, with compliance determined solely by adherence to contract requirements. No specific quality standards, preservation protocols, or MIL-STDs are cited in the documentation, though barcoding is implied through standardized logistics identifiers. The contract references unattached addenda for special requirements, and while no statement of work or evaluation factors are provided, administrative details confirm the order is processed under commercial item acquisition procedures with no option quantities or extended performance periods.